Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.32 |
| ▸ | GGT1 | P19440 | 1/20 | 0.32 |
| ▸ | CPB1 | P15086 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1953730 | 0.98 | CPB2 (0.32) | CPB2GGT1CPB1 | |
| SCHEMBL199875 | 0.90 | — | — | |
| Acetic Acid SCHEMBL22342078 | 0.85 | CPB2 (0.33) | CPB2GGT1CPB1 | |
| Acetic Acid SCHEMBL896270 | 0.85 | CPB2 (0.33) | CPB2GGT1CPB1 | |
| Acetic Acid SCHEMBL896859 | 0.84 | CPB2 (0.32) | CPB2GGT1CPB1 | |
| Acetic Acid SCHEMBL2347225 | 0.84 | CPB2 (0.32) | CPB2GGT1CPB1 | |
| Acetic Acid SCHEMBL28616089 | 0.84 | CPB2 (0.32) | CPB2GGT1CPB1 | |
| SCHEMBL477661 | 0.80 | CA12 (0.38) | ALDH1A1 | |
| SCHEMBL11741158 | 0.80 | — | — | |
| SCHEMBL10891054 | 0.78 | LMNA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3137485-A1 | CHELATOR MODIFIED MAGNETIC SILICA NANOPARTICLES, THEIR USE AND PREPARATION | Universidade de Aveiro (PT) | 2017-03-08 | — | — | EP | claimed |
| WO-2015166415-A1 | CHELATOR MODIFIED MAGNETIC SILICA NANOPARTICLES, THEIR USE AND PREPARATION | UNIVERSIDADE DE AVEIRO (PT) | 2015-11-05 | — | — | WO | claimed |
| EP-3137485-A1 | CHELATOR MODIFIED MAGNETIC SILICA NANOPARTICLES, THEIR USE AND PREPARATION | Universidade de Aveiro (PT) | 2017-03-08 | — | — | EP | disclosed |
| WO-2015166415-A1 | CHELATOR MODIFIED MAGNETIC SILICA NANOPARTICLES, THEIR USE AND PREPARATION | UNIVERSIDADE DE AVEIRO (PT) | 2015-11-05 | — | — | WO | disclosed |
| US-7361275-B2 | Use of derivatized nanoparticles to minimize growth of micro-organisms in hot filled drinks | EASTMAN KODAK COMPANY (US) | 2008-04-22 | — | — | US | disclosed |
| US-7357979-B2 | Composition of matter comprising polymer and derivatized nanoparticles | EASTMAN KODAK COMPANY (US) | 2008-04-15 | — | — | US | disclosed |
| WO-2006075995-A2 | ARTICLE INHIBITING MICROBIAL GROWTH IN PHYSIOLOGICAL FLUIDS | EASTMAN KODAK COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2005111129-A2 | COMPOSITION COMPRISING POLYMER AND DERIVATIZED NANOPARTICLES | EASTMAN KODAK COMPANY (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005107501-A2 | ARTICLE FOR INHIBITING MICROBIAL GROWTH | EASTMAN KODAK COMPANY (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005099489-A2 | MINIMIZING GROWTH OF MICRO-ORGANISMS IN LIQUID NUTRIENTS BY LIMITATION OF ESSENTIAL METAL IONS | EASTMAN KODAK COMPANY (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050226913-A1 | Article for inhibiting microbial growth in physiological fluids | EASTMAN KODAK COMPANY | 2005-10-13 | — | — | US | disclosed |
| US-20050224419-A1 | Use of derivatized nanoparticles to minimize growth of micro-organisms in hot filled drinks | EASTMAN KODAK COMPANY | 2005-10-13 | — | — | US | disclosed |
| US-20050228099-A1 | Composition of matter comprising polymer and derivatized nanoparticles | EASTMAN KODAK COMPANY | 2005-10-13 | — | — | US | disclosed |
| US-20050224417-A1 | Use of derivatized nanoparticles to minimize growth of micro-organisms in hot filled drinks | EASTMAN KODAK COMPANY | 2005-10-13 | — | — | US | disclosed |
| US-20050226911-A1 | Article for inhibiting microbial growth in physiological fluids | EASTMAN KODAK COMPANY | 2005-10-13 | — | — | US | disclosed |
| US-20050226967-A1 | Article for inhibiting microbial growth | EASTMAN KODAK COMPANY | 2005-10-13 | — | — | US | disclosed |
| US-20050224416-A1 | Use of derivatized nanoparticles to minimize growth of micro-organisms in hot filled drinks | NPEC INC. | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050226913-A1 | Article for inhibiting microbial growth in physiological fluids | FABP2, FABP1, MIF | CPB2 439/4885GGT1 839/4885CPB1 635/4885 |
| US-20050226911-A1 | Article for inhibiting microbial growth in physiological fluids | FABP2, FABP1, FABP6 | CPB2 243/4885GGT1 889/4885CPB1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.